New insider Hurly Stephen A claimed ownership of 5,000 shares (SEC Form 3)
$LVTX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 01/01/2025 |
3. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Shares | 5,000 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Share Options (Right to Buy) | (1) | 02/11/2030 | Common Shares | 232,934 | $2.35(2) | D | |
| Share Options (Right to Buy) | (3) | 12/16/2030 | Common Shares | 134,368 | $2.35(2) | D | |
| Share Options (Right to Buy) | (4) | 12/16/2030 | Common Shares | 360,451 | $2.35(2) | D | |
| Share Options (Right to Buy) | (5) | 12/20/2031 | Common Shares | 310,000 | $5.1 | D | |
| Share Options (Right to Buy) | (6) | 12/22/2032 | Common Shares | 800,000 | $3.77 | D | |
| Share Options (Right to Buy) | (7) | 01/18/2034 | Common Shares | 310,210 | $1.59 | D | |
| Explanation of Responses: |
| 1. Fully vested and immediately exercisable. |
| 2. Converted to U.S. dollars based on an exchange rate of 1.00 euro = $1.0389 (rounded to the nearest whole cent), the foreign exchange reference rate on December 31, 2024 as reported by the European Central Bank. Each option may be exercised for a price of 2.26 euros per share. |
| 3. 33,592 of the shares underlying the option vested on December 16, 2021 and the remainder vests in 36 equal monthly installments beginning on January 16, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. |
| 4. 90,113 of the shares underlying the option vested on March 17, 2022 and the remainder vests in 36 equal monthly installments beginning on April 17, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. |
| 5. The shares underlying the option vest in 48 equal monthly installments beginning on January 1, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. |
| 6. The shares underlying the option vest in 48 equal monthly installments beginning on February 1, 2023, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. |
| 7. The shares underlying the option vest in 48 equal monthly installments beginning on February 19, 2024, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. |
| /s/ Amy Garabedian, Attorney-in-Fact | 01/02/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||